全身性エリテマトーデス・ループス腎炎:疫学予測(~2028年)

◆英語タイトル:Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2028
◆商品コード:GDATA20MY1137
◆発行会社(リサーチ会社):GlobalData
◆発行日:2020年1月31日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,995 ⇒換算¥423,470見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,990 ⇒換算¥846,940見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD11,985 ⇒換算¥1,270,410見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2028
Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ system, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. Because of its dynamic nature, this disease has an unpredictable natural course leading to high rates of morbidity and even death (Bertsias, Cervera and Boumpas, 2012; Bhattacharya et al., 2011). Lupus nephritis (LN) or lupus glomerulonephritis is a complication of SLE in which the kidneys are affected. LN is a major contributor to morbidity and mortality among SLE patients (Bhattacharya et al., 2011; O’Neill and Cervera, 2010).

GlobalData epidemiologists utilized historical data obtained from peer-reviewed articles and reports to build the forecast for the diagnosed incident cases and the diagnosed prevalent cases of SLE and LN in the 7MM. GlobalData epidemiologists applied the incidence and prevalence of SLE and LN drawn from the above sources to each country’s population to calculate the number of estimated diagnosed incident cases and diagnosed prevalent cases for SLE and LN.

The following data describes the epidemiology of SLE and LN. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of SLE from 571,021 cases in 2018 to 600,663 cases in 2028, at an Annual Growth Rate (AGR) of 0.52%. When examining the AGR of diagnosed prevalence of SLE in individual markets, GlobalData epidemiologists forecast that the UK will see the highest AGR of 0.79% during the forecast period, while Germany will show the lowest negative AGR of 0.12%. In 2018, the 7MM had 98,620 diagnosed prevalent cases of LN, expected to increase to 102,939 diagnosed prevalent cases by 2028, at an AGR of 0.44%.

Scope

- The Systemic Lupus Erythematosus and Lupus Nephritis Epidemiology Report provides an overview of the risk factors and global trends of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of SLE segmented by age, and sex, and the diagnosed prevalent cases are further segmented by severity.
- The report also includes a 10-year epidemiological forecast for various comorbidities of SLE. An epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of LN among pediatric population and adult population for the 7MM is also incorporated.
- Additionally, the report includes the diagnosed prevalent cases of LN segmented by World Health Organization (WHO) and International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification into Classes I-VI.
- The SLE and LN epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
- The Epidemiology report is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the report supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The SLE and LN Epidemiology series will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global SLE and LN markets.
- Quantify patient populations in the global SLE and LN markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SLE and LN therapeutics in each of the markets covered.
- Understand magnitude of SLE and LN population by its severity.

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Systemic Lupus Erythematosus and Lupus Nephritis: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of SLE
3.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SLE
3.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SLE by Severity
3.4.6 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SLE by Comorbidities
3.4.7 Forecast Assumptions and Methods: Diagnosed Incident Cases of LN
3.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of LN
3.4.9 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of LN by Severity, Based on WHO Classifications
3.4.10 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of LN by Severity, Based on ISN/RPS Classification
3.5 Epidemiological Forecast for SLE and LN (2018-2028)
3.5.1 Diagnosed Incident Cases of SLE
3.5.2 Age-Specific Diagnosed Incident Cases of SLE
3.5.3 Sex-Specific Diagnosed Incident Cases of SLE
3.5.4 Diagnosed Incident Cases of LN
3.5.5 Diagnosed Prevalent Cases of SLE
3.5.6 Age-Specific Diagnosed Prevalent Cases of SLE
3.5.7 Sex-Specific Diagnosed Prevalent Cases of SLE
3.5.8 Diagnosed Prevalent Cases of SLE by Severity
3.5.9 Diagnosed Prevalent Cases of SLE by Comorbidities
3.5.10 Diagnosed Prevalent Cases of LN
3.5.11 Diagnosed Prevalent Cases of LN by Severity, Based on WHO Classifications
3.5.12 Diagnosed Prevalent Cases of LN by Severity, Based on ISN/RPS Classifications
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research – Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer

List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for SLE
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed for Severity of SLE, By Country
Table 5: High-Prescribing Physicians (non-KOLs) Surveyed for Comorbidities of SLE, By Country

【掲載企業】



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[全身性エリテマトーデス・ループス腎炎:疫学予測(~2028年)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆